Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
2025-525068-13-00· 2. fázis· Universitair Medisch Centrum Groningen· Forrás
Toboroz
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
2025-524283-38-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· 3. fázis· Milestone Pharmaceuticals Inc.· Forrás
Még nem toboroz
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· 3. fázis· Genmab A/S· Forrás
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Még nem toboroz
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Fut, nem toboroz
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· 3. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
NCT07472868· 3. fázis· Catharina Ziekenhuis Stichting· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
2025-520518-79-00· 2. fázis· Novartis Pharma AG· Forrás
Toboroz
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
NCT07107529· 2. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602· 3. fázis· NewAmsterdam Pharma· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
T3-4-Hypo trial
2024-513883-24-00· 3. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949· 2. fázis· Acesion Pharma· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
ASPIRING
2024-516188-10-00· 4. fázis· University Of Edinburgh· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
NCT07018661· 2/3. fázis· Leiden University Medical Center· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial
2024-517343-31-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)
NCT06549426· 3. fázis· University of Twente· Forrás
Toboroz
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01· 3. fázis· Shanghai Junshi Biosciences Co. Ltd.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149· 4. fázis· Insel Gruppe AG, University Hospital Bern· Forrás
Toboroz
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· 3. fázis· AstraZeneca· Forrás
Toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514· 3. fázis· Summit Therapeutics· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).
2024-518171-59-00· 4. fázis· Canisius Wilhelmina Ziekenhuis· Forrás
Toboroz
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· 3. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
The Effect of ColcHicine on the Incidence of Knee or Hip Replacements
NCT06578182· 3. fázis· Sint Maartenskliniek· Forrás
Toboroz
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance
2023-507489-20-00· 4. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
Ulipristal versus surgery for symptomatic uterine fibroids
2024-512602-26-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
2024-514055-15-00· 4. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
2023-510312-40-00· 4. fázis· Academisch Ziekenhuis Leiden· Forrás
Toboroz
Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial
NCT04834388· 2. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemic Treatment for early-stage REctal Cancer?
2024-514620-17-00· 2. fázis· Radboud universitair medisch centrum Stichting· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Showing 50 of 89.